Novacyt — Director's Dealing 2026

Mar 30, 2026

National Storage Mechanism | Additional information

RNS Number : 6764Y

Novacyt S.A.

30 March 2026

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France, and Manchester, UK - 30 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has been notified that, on 26 and 27 March 2026, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Average price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital
Lyn Rees	CEO	73,379	€0.3899	73,379	0.00%
John Brown	Chairman	73,762	€0.3899	73,762	0.00%
Ian Gilham	NED	28,750	£0.34415	28,750	0.00%

Contacts

Novacyt SA			https://novacyt.com/investors
Lyn Rees, Chief Executive Officer			Via Walbrook PR
Steve Gibson, Chief Financial Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)				+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Singer Capital Markets (Joint Broker)				+44 (0) 20 7496 3000
Phil Davies / James Fischer / Samed Ethemi
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit		+33 (1) 42 22 10 10 [email protected] / [email protected]
Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings			+44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7584 391 303  +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests ·    Precision Medicine: DPYD genotyping assay ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: ·    Ranger® Technology: automated DNA sample preparation and target enrichment technology ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: ·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry ·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1)    Lyn Rees

2)    John Brown

3)    Ian Gilham

1)    CEO

2)    Chairman

3)    NED

2.

Reason for the Notification

a)

Position/status

See 1(a) - classified as a PDMR of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Novacyt S.A.

b)

LEI

213800BWAC2BF295EG28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of €1/15 each

Identification code

FR0010397232

b)

Nature of the transaction

Acquisition of Ordinary Shares

c)

Price(s) and volume(s)

1)    Lyn Rees

2)    John Brown

3)    Ian Gilham

Price	Volume
€0.3817	15,149
€0.3919	56,438
€0.3945	1,792

Price	Volume
€0.3817	15,228
€0.3919	56,732
€0.3950	1,802

Price	Volume
£0.34415	28,750

d)

Aggregated information:

· Aggregated volume

· Price

1)    Lyn Rees

2)    John Brown

3)    Ian Gilham

Price	Volume
€0.3899	73,379

Price	Volume
€0.3899	73,762

Price	Volume
£0.34415	28,750

e)

Date of the transaction

1 & 2) 26 and 27 March 2026 

3) 27 March 2026

f)

Place of the transaction

1 & 2) Euronext and 3) AIM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHWPUMPWUPQGWU